Total Payments
$262,141
2024 Payments
$46,482
Companies
31
Transactions
221
Medicare Patients
5,621
Medicare Billing
$2.0M
Payment Breakdown by Category
Consulting$204,210 (77.9%)
Research$24,647 (9.4%)
Other$18,393 (7.0%)
Food & Beverage$8,735 (3.3%)
Travel$6,156 (2.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $204,210 | 76 | 77.9% |
| Unspecified | $24,647 | 12 | 9.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,393 | 4 | 7.0% |
| Food and Beverage | $8,735 | 112 | 3.3% |
| Travel and Lodging | $6,156 | 17 | 2.3% |
Payments by Type
General
$237,494
209 transactions
Research
$24,647
12 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ThromboGenics, Inc. | $39,000 | 10 | $0 (2019) |
| F. Hoffmann-La Roche AG | $36,996 | 15 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $32,134 | 37 | $0 (2024) |
| Genentech, Inc. | $26,056 | 28 | $0 (2022) |
| Allergan, Inc. | $20,916 | 25 | $0 (2020) |
| Hoffmann-La Roche Limited | $15,700 | 4 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $10,050 | 3 | $0 (2023) |
| Novartis Pharma AG | $9,675 | 2 | $0 (2022) |
| Amgen Inc. | $9,286 | 9 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $9,080 | 9 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $46,482 | 63 | Regeneron Pharmaceuticals, Inc. ($18,274) |
| 2023 | $29,224 | 21 | F. Hoffmann-La Roche AG ($6,680) |
| 2022 | $36,632 | 23 | Hoffmann-La Roche Limited ($11,775) |
| 2021 | $21,362 | 15 | Novartis Pharma AG ($5,375) |
| 2020 | $5,097 | 6 | Regeneron Pharmaceuticals, Inc. ($3,510) |
| 2019 | $48,791 | 43 | Allergan Inc. ($16,488) |
| 2018 | $33,052 | 27 | ThromboGenics, Inc. ($12,000) |
| 2017 | $41,502 | 23 | ThromboGenics, Inc. ($18,000) |
All Payment Transactions
221 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $197.50 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $3,760.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,880.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $110.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $16.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/15/2024 | Bausch & Lomb Americas Inc. | MIEBO (Drug), XIIDRA | Food and Beverage | In-kind items and services | $142.52 | General |
| Category: Ophthalmology | ||||||
| 12/02/2024 | EyePoint Pharmaceuticals US, Inc. | EYP-1901 (Drug) | Consulting Fee | Cash or cash equivalent | $462.50 | General |
| Category: Wet Age Related Macular Degeneration (wAMD) | ||||||
| 11/23/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $164.07 | General |
| Category: Ophthalmology | ||||||
| 10/24/2024 | Ocular Therapeutix, Inc. | DEXTENZA (Drug) | Food and Beverage | In-kind items and services | $29.92 | General |
| Category: Corticosteroid intracanalicular insert | ||||||
| 10/19/2024 | BioCryst Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $39.75 | General |
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $149.66 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Travel and Lodging | In-kind items and services | $337.10 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $122.99 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $97.43 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $52.95 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $52.95 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,874.36 | Research |
| Study: Treatment Patterns and Long-term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $752.00 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $668.00 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $306.36 | Research |
| Study: VA2 PhIII Yosemite | ||||||
| 09/24/2024 | LEICA MICROSYSTEMS INC. | Surgical Microscopes (Device) | Food and Beverage | In-kind items and services | $23.44 | General |
| Category: Devices | ||||||
| 09/13/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological), EYLEA HD | Food and Beverage | In-kind items and services | $105.22 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/12/2024 | Carl Zeiss Meditec USA, Inc. | CIRRUS HD-OCT (Device), CLARUS | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: Optical Tomography | ||||||
| 09/12/2024 | Carl Zeiss Meditec USA, Inc. | CIRRUS HD-OCT (Device), CLARUS | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: Optical Tomography | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $10,322 | 4 |
| Long Term Clinical Outcomes of anti-VEGF Therapy for Retinal Vein Occlusion: An Overview of Current Data | F. Hoffmann-La Roche AG | $6,680 | 1 |
| Treatment Patterns and Long-term Outcomes with Anti-VEGF Therapy for Retinal Vein Occlusion: An Analysis of the Vestrum Database | F. Hoffmann-La Roche AG | $2,874 | 1 |
| VA2 PhIII Yosemite | F. Hoffmann-La Roche AG | $2,405 | 5 |
| A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY | F. Hoffmann-La Roche AG | $2,366 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,730 | 3,618 | $4.3M | $635,275 |
| 2022 | 7 | 1,584 | 3,160 | $3.4M | $529,247 |
| 2021 | 9 | 1,421 | 2,819 | $3.0M | $470,520 |
| 2020 | 8 | 886 | 1,759 | $2.0M | $324,062 |
Total Patients
5,621
Total Services
11,356
Medicare Billing
$2.0M
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 57 | 713 | $3.0M | $492,485 | 16.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 449 | 657 | $381,060 | $47,841 | 12.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 63 | 384 | $347,520 | $36,507 | 10.5% |
| 92134 | Imaging of retina | Office | 2023 | 490 | 962 | $357,790 | $31,434 | 8.8% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 489 | 696 | $83,020 | $13,919 | 16.8% |
| 92002 | New patient problem focused exam of visual system | Office | 2023 | 108 | 108 | $61,560 | $7,860 | 12.8% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 20 | 20 | $14,000 | $2,573 | 18.4% |
| 92250 | Photography of the retina | Office | 2023 | 38 | 57 | $25,935 | $1,741 | 6.7% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 16 | 21 | $17,160 | $914.10 | 5.3% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2022 | 55 | 570 | $2.4M | $409,175 | 17.2% |
| 92012 | Established patient problem focused exam of visual system | Office | 2022 | 448 | 662 | $383,960 | $45,785 | 11.9% |
| 92134 | Imaging of retina | Office | 2022 | 479 | 904 | $266,573 | $28,548 | 10.7% |
| 67028 | Injection of drug into eye | Office | 2022 | 59 | 301 | $272,405 | $28,391 | 10.4% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 451 | 627 | $69,597 | $12,043 | 17.3% |
| 92002 | New patient problem focused exam of visual system | Office | 2022 | 60 | 60 | $34,200 | $4,168 | 12.2% |
| 92250 | Photography of the retina | Office | 2022 | 32 | 36 | $16,380 | $1,137 | 6.9% |
| J0178 | Injection, aflibercept, 1 mg | Office | 2021 | 52 | 484 | $2.0M | $357,456 | 17.7% |
| 92012 | Eye and medical examination for diagnosis and treatment, established patient | Office | 2021 | 386 | 587 | $340,460 | $43,694 | 12.8% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 406 | 789 | $232,648 | $26,268 | 11.3% |
| 67028 | Injection of drug into eye | Office | 2021 | 59 | 273 | $248,423 | $26,117 | 10.5% |
| 92201 | Extended examination of eye with drawing of retina | Office | 2021 | 330 | 459 | $50,949 | $9,443 | 18.5% |
| 92002 | Eye and medical examination for diagnosis and treatment, new patient | Office | 2021 | 52 | 52 | $29,640 | $3,566 | 12.0% |
| 92250 | Photography of the retina | Office | 2021 | 55 | 80 | $36,400 | $2,445 | 6.7% |
| 92202 | Extended examination of eye with drawing of optic nerve and surrounding area (macula) | Office | 2021 | 69 | 80 | $5,600 | $858.88 | 15.3% |
| 76512 | Ultrasound of eye disease, growth, or structure | Office | 2021 | 12 | 15 | $12,090 | $671.70 | 5.6% |
About Dr. Michael Ip, MD
Dr. Michael Ip, MD is a Ophthalmology healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 02/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982670402.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Ip, MD has received a total of $262,141 in payments from pharmaceutical and medical device companies, with $46,482 received in 2024. These payments were reported across 221 transactions from 31 companies. The most common payment nature is "Consulting Fee" ($204,210).
As a Medicare-enrolled provider, Ip has provided services to 5,621 Medicare beneficiaries, totaling 11,356 services with total Medicare billing of $2.0M. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Pasadena, CA
- Active Since 02/24/2006
- Last Updated 01/23/2025
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1982670402
Products in Payments
- Jetrea (Drug) $39,000
- Lucentis (Biological) $29,376
- EYLEA (Biological) $23,571
- BEOVU (Drug) $13,368
- Non-Covered Product (Drug) $12,919
- EYLEA HD (Biological) $8,676
- CIRRUS HD-OCT (Device) $6,195
- OZURDEX (Drug) $5,740
- BUPARLISIB (Drug) $5,247
- VABYSMO (Drug) $4,900
- Syfovre (Drug) $4,887
- YUTIQ (Drug) $4,865
- ARTEVO 800 (Device) $4,500
- Iluvien (Drug) $4,200
- Rhopressa (Drug) $3,656
- Vabysmo (Drug) $2,750
- EYP-1901 (Drug) $1,949
- PROKERA (Device) $1,500
- XIPERE (Drug) $597.18
- Constellation (Device) $300.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Pasadena
Srinivas Sadda, Md, MD
Ophthalmology — Payments: $1.3M
Ophthalmology $1.3M
Dr. Sahar Bedrood, Md,Phd, MD,PHD
Ophthalmology — Payments: $237,078
Ophthalmology $237,078
Jeffrey Hong, Md, MD
Ophthalmology — Payments: $75,796
Ophthalmology $75,796
Alfredo Sadun, M.d., Ph.d, M.D., PH.D
Ophthalmology — Payments: $27,619
Ophthalmology $27,619
Eugene Chang, Md, MD
Ophthalmology — Payments: $14,875
Ophthalmology $14,875
Dr. Payam Amini, M.d, M.D
Ophthalmology — Payments: $14,341
Ophthalmology $14,341